These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 37760438)

  • 21. Surgical excision margins for melanoma in situ.
    Akhtar S; Bhat W; Magdum A; Stanley PR
    J Plast Reconstr Aesthet Surg; 2014 Mar; 67(3):320-3. PubMed ID: 24444795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lentigo Maligna: Clinical Presentation and Appropriate Management.
    Iznardo H; Garcia-Melendo C; Yélamos O
    Clin Cosmet Investig Dermatol; 2020; 13():837-855. PubMed ID: 33223843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ingenol Mebutate for Lentigo Maligna: A Case Report.
    Gadaldi K; Feldmeyer L; Yawalkar N; Hunger RE
    Dermatology; 2016; 232 Suppl 1():24-8. PubMed ID: 27513527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases.
    Bene NI; Healy C; Coldiron BM
    Dermatol Surg; 2008 May; 34(5):660-4. PubMed ID: 18261099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
    Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
    Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical Imiquimod Treatment of Lentigo Maligna.
    Ventura F; Rocha J; Fernandes JC; Pardal F; Brito C
    Case Rep Dermatol; 2009 Oct; 1(1):78-81. PubMed ID: 20652120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of lentigo maligna with imiquimod 5% cream.
    Hopson B; Richey D; Sajben FP
    J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy for lentigo maligna and lentigo maligna melanoma - a systematic review.
    Hendrickx A; Cozzio A; Plasswilm L; Panje CM
    Radiat Oncol; 2020 Jul; 15(1):174. PubMed ID: 32664998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical Imiquimod for Management of Recurrent Lentigo Maligna Melanoma in Situ.
    Bartenjev MS; Isaković-Vidović S; Bartenjev I
    Acta Dermatovenerol Croat; 2020 Jul; 28(1):34-37. PubMed ID: 32650849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of surgical margins for lentigo maligna versus melanoma in situ.
    Kunishige JH; Doan L; Brodland DG; Zitelli JA
    J Am Acad Dermatol; 2019 Jul; 81(1):204-212. PubMed ID: 31014825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lentigo maligna treated with 5% imiquimod cream].
    Martín T; Ojeda A; Martínez S; Vera A
    Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma.
    Malhotra R; Chen C; Huilgol SC; Hill DC; Selva D
    Ophthalmology; 2003 Oct; 110(10):2011-8. PubMed ID: 14522781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
    Chambers M; Swetter SM; Baker C; Saunders E; Chapman MS
    J Drugs Dermatol; 2021 Mar; 20(3):346-348. PubMed ID: 33683087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of lentigo maligna with imiquimod before staged excision.
    Cotter MA; McKenna JK; Bowen GM
    Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical and Intralesional Immunotherapy for the Management of Skin Cancer in Special Locations: Lips and Eyelids.
    Buján Bonino C; Rodríguez-Blanco I; Sánchez-Aguilar Rojas D; Vázquez Veiga HA; Flórez Á
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management.
    Guitera P; Collgros H; Madronio CM; Goumas C; Mann GJ; Watts CG; Pereira AR; Armstrong BK; Drummond M; Morton RL; Scolyer RA; Menzies SW; Thompson JF; Cust AE
    Australas J Dermatol; 2019 May; 60(2):118-125. PubMed ID: 30302753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical management of melanoma-in-situ using a staged marginal and central excision technique.
    Möller MG; Pappas-Politis E; Zager JS; Santiago LA; Yu D; Prakash A; Kinal A; Clark GS; Zhu W; Puleo CA; Glass LF; Messina JL; Sondak VK; Cruse CW
    Ann Surg Oncol; 2009 Jun; 16(6):1526-36. PubMed ID: 19050971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance.
    Mora AN; Karia PS; Nguyen BM
    J Am Acad Dermatol; 2015 Aug; 73(2):205-12. PubMed ID: 26088690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for Reducing Final Surgical Defect Sizes in the Treatment of Lentigo Maligna.
    Sampson BP; Bowen GM
    Dermatol Surg; 2020 Apr; 46(4):537-545. PubMed ID: 31464705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Staged margin-controlled excision (SMEX) for lentigo maligna melanoma in situ.
    Beveridge J; Taher M; Zhu J; Mahmood MN; Salopek TG
    J Surg Oncol; 2018 Jul; 118(1):144-149. PubMed ID: 29936706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.